Niagen Bioscience, Inc. - 8-K Filing
Niagen Bioscience reports Q3 2026 net sales of $27.2 million and positive adjusted EBITDA of $0.5 million. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $CDXC